PATENT CLAIM ANALYSIS

Application Number: 15753045
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "252160"]

Abstract:
The present disclosure relates to pharmaceutical combinations comprising (a) a cyclin dependent kinase 4/6 (CDK4/6) inhibitor compound, and (b) an epidermal growth factor receptor (EGFR) inhibitor, for the treatment or prevention of cancer. The disclosure also provides related pharmaceutical compositions, uses, and methods of treatment or prevention of cancer.

Claim (Index 1):
A pharmaceutical combination comprising:\n (a) a first compound having the structure of formula (I): or a pharmaceutically acceptable salt or solvate thereof, and (b) a second compound having the structure of formula (Il): or a pharmaceutically acceptable salt or solvate thereof.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 88.0
- Lexical Diversity: 1.53659
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15755140', '14414998', '15755122', '13799706', '15882620']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7714264738399723
- 35 USC 102 Novelty (BERT): 0.5248892316074729
- Combined Prediction Score: 0.7467727496167224
- Mean Citation Score: 284.788728
- Max Citation Score: 340.7501200000001
- Similarity Product: 254.9196474641992

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test